Citius Pharmaceuticals, Inc.
For the period ended Sep 30, 2025. Filed Dec 23, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Dec 23, 2025
CTXR$0.53-3.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
SEPTEMBER 30, 2025 AND 2024
| 2025 | 2024 | |
|---|---|---|
| ASSETS | ||
| Current Assets: | ||
| Cash and cash equivalents | $4,252,290 | $3,251,880 |
| Inventory | 22,286,693 | 8,268,766 |
| Prepaid expenses | 1,395,490 | 2,700,000 |
| Total Current Assets | 27,934,473 | 14,220,646 |
| Operating lease right-of-use asset, net | 818,694 | 246,247 |
| Other Assets: | ||
| Deposits | 38,062 | 38,062 |
| In-process research and development | 92,800,000 | 92,800,000 |
| Goodwill | 9,346,796 | 9,346,796 |
| Total Other Assets | 102,184,858 | 102,184,858 |
| Total Assets | $130,938,025 | $116,651,751 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current Liabilities: | ||
| Accounts payable | $13,693,692 | $4,927,211 |
| License payable | 22,650,000 | 28,400,000 |
| Accrued expenses | 4,190,253 | 17,027 |
| Accrued compensation | 3,292,447 | 2,229,018 |
| Note payable | 1,000,000 | — |
| Operating lease liability | 88,348 | 241,547 |
| Total Current Liabilities | 44,914,740 | 35,814,803 |
| Deferred tax liability | 7,770,760 | 6,713,800 |
| Operating lease liability – non current | 724,925 | 21,318 |
| Total Liabilities | 53,410,425 | 42,549,921 |
| Commitments and Contingencies | ||
| Stockholders’ Equity: | ||
| Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding | — | — |
| Common stock - $0.001 par value; 250,000,000 and 16,000,000 shares authorized at September 30, 2025 and 2024, respectively; 18,067,744 and 7,247,243 shares issued and outstanding at September 30, 2025 and 2024, respectively | 18,068 | 7,247 |
| Additional paid-in capital | 306,336,239 | 271,440,421 |
| Accumulated deficit | (238,804,129) | (201,370,218) |
| Total Citius Pharmaceuticals, Inc. Stockholders’ Equity | 67,550,178 | 70,077,450 |
| Non-controlling interest | 9,977,422 | 4,024,380 |
| Total Equity | 77,527,600 | 74,101,830 |
| Total Liabilities and Equity | $130,938,025 | $116,651,751 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.